Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72

Benzinga Newsdesk www.benzinga.com Positive 86.5%

Neg 0% Neu 0% Pos 86.5%

Cantor Fitzgerald analyst Kristen Kluska maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $61 to $72.